Phase II study of carboplatin and weekly paclitaxel combination chemotherapy in advanced non-small cell lung cancer: A Kansai Clinical Oncology Group study

Lung Cancer

Volumn 44, Issue 3, 2004, Pages 355-362

  Hirabayashi, Masataka ^a   Endoh, Kazuo ^a   Teramachi, Masayoshi ^a   Okuda, Masato ^b   Yamaguchi, Kazuyuki ^c   Fukuda, Kohji ^d   Tokuhisa, Hidetoshi ^e   Kagioka, Hitoshi ^e   Nakai, Naoharu ^f   Nakade, Masaharu ^g  

^a Hyogo Prefectural Tsukaguchi Hospital   (Japan)

^b KYOTO UNIVERSITY   (Japan)

^c KANSAI MEDICAL UNIVERSITY   (Japan)

^d SUMITOMO HOSPITAL   (Japan)

^e Kitano Hospital   (Japan)

^f Saiseikai Noe Hospital   (Japan)

^g OSAKA RED CROSS HOSPITAL   (Japan)

Author keywords

Carboplation; Chemotherapy; NSCLC; Weekly paclitaxel

Indexed keywords

CARBOPLATIN; DEXAMETHASONE; DIPHENHYDRAMINE; DOCETAXEL; GEMCITABINE; NAVELBINE; PACLITAXEL; RANITIDINE;

ADULT; ADVANCED CANCER; AGED; ALLERGIC REACTION; ALOPECIA; ANEMIA; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER PATIENT; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; DEATH; DIARRHEA; DISEASE SEVERITY; DRUG EFFICACY; DUODENUM ULCER; FEBRILE NEUTROPENIA; FEMALE; HEMOPTYSIS; HUMAN; LETHARGY; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MALE; MYALGIA; NAUSEA AND VOMITING; NEUROPATHY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PACLITAXEL; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 2342533017     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2003.12.001     Document Type: Article

References (39)

1. Kelly K., Crowley J., Bunn P.A., Presant C.A., Grevstad P.K., Moinpour C.M., et al. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: a Southwest Oncology Group trial. J. Clin. Oncol. 19:2001;3210-3218
2. Schiller J.H., Harrington D., Belani C.P., Langer C., Sandler A., Krook J.K., et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. New Engl. J. Med. 346:2002;92-98
3. Liebmann J.E., Cook J.A., Lipschultz C., Teague D., Fisher J., Mitchell J.B. Cytotoxic studies of paclitaxel in human tumor cell lines. Br. J. Cancer. 68:1993;1104-1109
4. Georgiadis M.S., Russell E.K., Gazdar A.F., Johnson B.E. Paclitaxel cytotoxicity against human lung cancer cell lines increases with prolonged exposure durations. Clin. Cancer Res. 3:1997;449-454
5. Wilson W.H., Berg S.L., Bryant G., Wittes R.E., Bates S., Fojo A., et al. Paclitaxel in doxorubicin-refractory or mitoxantrone-refractory breast cancer: a phase I/II trial of 96-hour infusion. J. Clin. Oncol. 12:1994;1621-1629
6. Seidman A.D., Hochhouser D., Gollub M., Edelman B., Yao T.J., HUdis C.A., et al. Ninety-six-hour paclitaxel infusion after progression during short taxane exposure: a phase II pharmacokinetic and pharmacodynamic study in metastatic breast cancer. J. Clin. Oncol. 14:1996;1877-1884
7. Gilewski T, Norton L. Cytokinetics and breast cancer chemotherapy. In: Harris JR, Lippman ME, Morrow M, et al., editors. Diseases of the breast. Philadelphia, PA: Lippincott/Raven, 1996. p. 1877-84.
8. Jordan M.A., Wendell K., Gardiner S., Derry W.B., Copp H., Wilson L. Mitotic block in Hela cells by low concentrations of paclitaxel resilts in abnormal mitotic exit and apoptotic cell death. Cancer Res. 56:1996;816-825
9. Chang A.Y., Rubins J., Asbury R., Boros L., Hui L.F. Weekly paclitaxel in advanced non-small cell lung cancer. Semin. Oncol. 28(Suppl. 14):2001;10-13
10. Seidman A.D., Hudis C.A., Albanel J., Tong W., Tepler I., Currie V., et al. Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer. J. Clin. Oncol. 16:1998;3353-3361
11. Fennelly D., Aghajanian C., Shapiro F., O'Flaherty C., McKenzie M., O'Connor C., et al. Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer. J. Clin. Oncol. 15:1997;187-192
12. Hirabayashi M., Okuda M., Endoh K., Teramachi M., Yamaguchi K., Moriyarna M., et al. Dose finding study of carboplatin and weekly paclitaxel for advanced non-small cell lung cancer. Jpn. J. Cancer. 41:2001;767-772. (in Japanese)
13. Bookman M.A., Kloth D.D., Kover P.E., Smolinski S., Ozols R.F. Short-course intravenous prophylaxis for paclitaxel-related hypersensitivity reactions. Ann. Oncol. 8:1997;611-614
14. Klaasen U., Wilke H., Strumberg D., Eberhardt W., Korn M., Seeber S. Phase I study with a weekly 1 hour infusion of paclitaxel in heavily pretreated patients with metastatic breast and ovarian cancer. Eur. J. Cancer. 32A:1996;547-549
15. Calvert A.H., Newell D.R., Gumbrell L.A., O'Reilly S., Burnell M., Boxall F.E., et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J. Clin. Oncol. 7:1989;1748-1756
16. Jelliffe R.W. Letter: creatinine clearance: bedside estimate. Ann. Intern. Med. 79:1973;604-605
17. Simon R. Optimal two-stage designs for phase II clinical trials. Contr. Clin. Trials. 10:1989;1-10
18. World Health Organization. The WHO handbook for reporting results of cancer treatment. Geneva: World Health Organization, 1979.
19. Kaplan E.L., Meier P. Non-parametric estimation from incomplete observations. J. Am. Stat. Assoc. 53:1958;457-481
20. Green M.C., Buzdar A.U., Smith T., Ibrahim N.K., Valero V., Rosales M., et al. Weekly paclitaxel followed by FAC as primary systemic chemotherapy of operable breast cancer improves pathologic complete remission rates when compared to every 3-week paclitaxel therapy followed by FAC - final results of a prospective phase III randomized trial [abstract]. Proc. Am. Soc. Clin. Oncol. 21:2002;35a
21. Seidman A.D., Fornier M.N., Esteva F.J., Tan L., Kaptain S., Bach A., et al. Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. J. Clin. Oncol. 19:2001;2587-2595
22. Andersson H., Boman K., Ridderheim M., Rosenberg P., Sorbe B., Puistola U., et al. An updated analysis of a randomized study of single agent paclitaxel given weekly versus every 3 weeks to patients with ovarian cancer treated with prior platinum therapy [abstract]. Proc. Am. Soc. Clin. Oncol. 19:2000;380a
23. Fidias P., Supko J.G., Martins R., Boral A., Carey R., Grossbard M., et al. A phase II study of weekly paclitaxel in elderly patients with advanced non-small cell lung cancer. Clin. Cancer Res. 7:2001;3942-3949
24. Koumakis G., Demiri M., Barbounis V., Vassilomanolakis M., Gontikakis E., Pamouksoglou P., et al. Is weekly paclitaxel superior to paclitaxel given every 3 weeks? Results of a phase II trial. Lung Cancer. 35:2002;315-317
25. Vidal O.J., Alberola V., Ordono F., Villarroya T., Sanchez R., Encinas A., et al. Low-dose weekly paclitaxel in the treatment of unresectable or metastatic non-small cell lung cancer. Neurological and electrophysiological evaluation of neurotoxicity [abstract]. Proc. Am. Soc. Clin. Oncol. 20:2001;271b
26. Socinski M.A., Schell M.J., Bakri K., Peterman A., Lee J.H., Unger P., et al. Second-line, low-dose, weekly paclitaxel in patients with stage IIIB/IV nonsmall cell ling carcinoma who fail first-line chemotherapy with carboplatin plus paclitaxel. Cancer. 95:2002;1265-1273
27. Akerley W., Herndon J., Egorin M.J., Lyss A., Kindler H., Savarese D., et al. CALGB9731: phase II trial of weekly paclitaxel for advanced non-small cell lung cancer [abstract]. Proc. Am. Soc. Clin. Oncol. 18:1999;462a
28. Akerley W. Recent developments in weekly paclitaxel therapy in lung cancer. Curr. Oncol. Rep. 3:2001;165-169
29. Sandler A.B., Nemunaitis J., Denham C., Pawel J., Cormier Y., Gatzemeier U., et al. Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer. J. Clin. Oncol. 18:2000;122-130
30. Wozniak A.J., Crowley J.J., Balcerzak S.P., Weiss G.R., Spiridonidis C.H., Baker L.H., et al. Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer. A Southwest Oncology Group study. J. Clin. Oncol. 16:1998;2459-2465
31. Lilenbaum R.C., Herndon J., List M., Desch C., Watson D., Holland J., et al. Single-agent versus combination chemotherapy in advanced non-small cell lung cancer: a CALGB randomized trial of efficacy, quality of life, and cost-effectiveness [abstract]. Proc. Am. Soc. Clin. Oncol. 21:2002;1a
32. Sederholm C. Gemcitabine compared with gemcitabine plus carboplatin in advanced non-small cell lung cancer: a phase III study by the Swedish Lung Cancer Study Group [abstract]. Proc. Am. Soc. Clin. Oncol. 21:2002;291a
33. Georgoulias V., Ardavanis A., Agelidou M., Papadakis E., Rapti A., Palamidas P., et al. Preliminary analysis of a multicenter phase III trial comparing docetaxel versus docetaxel/cisplatin in patients with inoperable advanced and metastatic non-small cell lung cancer [abstract]. Proc. Am. Soc. Clin. Oncol. 21:2002;291a
34. Olver I.N., Donehower R.C., VanEcho D.A., Ettinger D.S., Aisner J. Phase II trial of carboplatin in non-small cell lung cancer. Cancer Treat. Rep. 70:1986;421-422
35. Loesch D., Robert N., Asmar L., Gregurich M.A., O'Rourke M., Dakhil S., et al. Phase II multicenter trial of a weekly paclitaxel and carboplatin regimen in patients with advanced breast cancer. J. Clin. Oncol. 20:2002;3857-3864
36. Scagliotti G.V., DeMarinis F., Rinaldi M., Crino L., Gridelli C., Ricci S., et al. Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J. Clin. Oncol. 20:2002;4285-4291
37. Bunn P.A., Kelly K. New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: a review of the literature and future directions. Clin. Cancer Res. 5:1998;1087-1100
38. Belani C.P., Barsti J., Perry M., Larocca R., Nattam S., Clark R., et al. Phase II multicenter randomized trial of weekly paclitaxel administered in combination with carboplatin followed by maintenance paclitaxel vs observation for patients with advanced & metastatic non-small cell lung cancer [abstract]. Proc. Am. Soc. Clin. Oncol. 20:2001;323a
39. Belani C.P. Interim analysis of a phase II study of induction weekly paclitaxel/carboplatin regimens followed by maintenance weekly paclitaxel for advanced and metastatic non-small cell lung cancer. Semin. Oncol. 28(Suppl. 14):2001;14-16